🇺🇸 FDA
Pipeline program

Placebo to MK-7240 (Tulisokibart), tulisokibart

MK-7240-011

Phase 3 small_molecule active

Quick answer

Placebo to MK-7240 (Tulisokibart), tulisokibart for Crohn’s Disease or Ulcerative Colitis is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Crohn’s Disease or Ulcerative Colitis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials